Session Information
Date: Monday, November 14, 2016
Title: Rheumatoid Arthritis – Clinical Aspects - Poster II: Co-morbidities and Complications
Session Type: ACR Poster Session B
Session Time: 9:00AM-11:00AM
Background/Purpose: Metabolic syndrome (MS) is a common comorbidity in patients with rheumatoid arthritis (RA). Several adipokines have been implied in the pathogenesis of MS on general population and rheumatic inflamatory disorders. Omentin-1 is an adipokine implied in reducing insulin resistance, and improving hypertension and dyslipidemia among general population. Nevertheless, the role of this adipokine in MS is not conclusive and there is no information about the association between serum levels of omentin-1 and the components of MS in RA. In order to test the hypothesis that serum omentin-1 levels are biomarkers of protection for MS the aim of the present study was to evaluate if serum omentin-1 levels are associated with the MS components in patients with RA.
Methods: In this cross-sectional study we included adult women with established RA (according to 1987 ACR criteria). Exclusion criteria were active infections, cancer, chronic renal failure, hepatic failure or pulmonary fibrosis. Thirty women with RA and MS (RA+MS) according to the NCEP-ATP III criteria were compared with 30 women with RA without MS (RA-MS) matched by range of age. Clinical and epidemiological characteristics were evaluated, as well as disease activity measured by DAS-28 index. Serum omentin-1 levels were determined by ELISA.
Results: Patients with RA+MS had higher body mass index compared with RA-MS (28.1 vs 24.4 kg/m2, p< 0.001). Serum omentin-1 levels were similar in patients with RA+MS compared with RA-MS (794 vs 941 ng/mL, respectively, p = 0.15). In the correlation between specific components of MS, serum omentin-1 levels correlated with higher diastolic blood pressure (rho= 0.22, p= 0.03) and higher HDL-cholesterol levels (rho= 0.20, p=0.05). After adjusting by age and disease duration, BMI was the major risk factor for MS in this patients (OR= 1.46, 95% CI= 1.06-1.99, p= 0.02), and serum omentin-1 levels did not achieve statistical significance.
Conclusion: No significant difference in omentin-1 levels in RA patients with and without MS was observed. However serum omentin-1 positively correlated with HDL-cholesterol and diastolic blood pressure. This implies the assumption that this adipokine influences some cardiovascular risk factors and should be evaluated in future studies.
To cite this abstract in AMA style:
Flores-Chavez A, Perez-Guerrero EE, Ramirez-Villafaña M, Trujillo X, Nava-Zavala AH, Garcia-Cobian TA, Alcaraz-Lopez MF, Salazar-Paramo M, Cardona-Muñoz EG, Totsuka-Sutto SE, Gonzalez-Lopez LDC, Gamez-Nava JI. Serum Omentin-1 Levels and Metabolic Syndrome in Women with Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/serum-omentin-1-levels-and-metabolic-syndrome-in-women-with-rheumatoid-arthritis/. Accessed .« Back to 2016 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/serum-omentin-1-levels-and-metabolic-syndrome-in-women-with-rheumatoid-arthritis/